Letter of Offer for Rights Issue

09.09.2026 BSE Limited, Dept. Corporate Services, P J Towers, Dalal Street, Mumbai-400001. Scrip Code: 526445 Dear Sir/ Madam, Subject: Submission of Letter of Offer of Rights Issue of the Partly paid-up Equity Shares of Indrayani Biotech Limited (‘the Company’) Further to our earlier announcement today, enclosing the Letter of Offer (“LOF”) in relation to the Rights Issue upto 3,25,25,897 partly paid-up Equity Shares of face value of ₹10/- each, at an issue price of ₹15/- per Equity Share each, aggregating up to ₹4878.88 Lakhs, an issue price of Rs. 15/- each (including the premium of Rs. 5/- each), on rights basis to the eligible equity shareholders of the Company in the ratio of 5 (Five) Rights Equity Shares for every 7 (Seven) fully paidup Equity Shares of Rs. 10/- each held by the Eligible Equity Shareholders in the Company as on the record date, i.e. April 28, 2026. We wish to inform you that Rights Issue Committee constituted by the Board of Directors of the Company for the Rights Issue (the “Rights Issue Committee”), has approved the Letter of Offer in respect of the aforementioned Rights Issue. In this regard, please find enclosed the soft copy of Letter of Offer dated September 09, 2026. The LOF will also be uploaded on the Company’s website at www.indrayani.com We request you to take the same on record. Thanking you, Yours Faithfully, For and Behalf of Indrayani Biotech Limited Swaminathan Govindarajan Whole-time Director DIN: 02481041 Block 1, 33, SIDCO Electronic Complex, Thiru Vi Ka Industrial Estate, Guindy, Chennai 600032 Ph: +91-44-24463751 / +91-44-22502146 | www.indrayani.com | info@indrayani.com | CIN: L40100TN1992PLC129301 LETTER OF OFFER Indrayani Biotech Limited For Eligible Equity Shareholders only Our Company was originally incorporated as “Indrayani Biotech Private Limited” at Pune, Maharashtra, as a Private Limited Company, under the provisions of the Companies Act, 1956, vide Certificate of Incorporation dated March 09, 1992, issued by the Registrar of Companies, Mumbai, Maharashtra. Subsequently Company was converted into public limited Company and the name of the Company was changed to “Indrayani Biotech Limited”, vide fresh Certificate of Incorporation dated April 09, 1992, issued by the Registrar of Companies, Mumbai, Maharashtra.For further details, please refer to the section titled “General Information” beginning on page 5 of this Letter of offer. SEPTEMBER 9, 2026 Indrayani Biotech Limited Registered Office: Module 33, Block 1, SIDCO Electronics Complex, Thiru Vi Ka Industrial Estate, Guindy, Chennai, 600032 Email id: cs@indrayani.com; Website: www.indrayani.com; CIN: L40100TN1992PLC129301 Contact Person: Mr. C S Shanmuga Sundar, Company Secretary & Compliance Officer PROMOTERS OF OUR COMPANY: Mr. G Swaminathan, Mr. Sayee Sundar Kasiraman, Mr. M Ramesh, Mr. Singarababu Indrakumar, Ms. Jothi Ramesh, Mr. V.Agathiyan, Ms. Uma Sundari, Mr. Dinesh Kumar, Mr. Thirumeni Thiruselvaraja, Mr. Logan and Ms. M.Ramya FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF INDRAYANI BIOTECH LIMITED (THE “COMPANY” OR THE “ISSUER”) ONLY Indrayani Biotech Limited (CIN- L40100TN1992PLC129301) Letter of Offer THE ISSUE ISSUE OF UPTO 3,25,25,897 PARTLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹ 10.00 EACH (“EQUITY SHARES”) OF INDRAYANI BIOTECH LIMITED (“INDRANIB” OR THE “COMPANY” OR THE “ISSUER”) FOR CASH AT A PRICE OF ₹ 15 PER EQUITY SHARE (INCLUDING PREMIUM OF ₹ 5 PER EQUITY SHARE) (“ISSUE PRICE”) FOR AN AGGREGATE AMOUNT NOT EXCEEDING ₹ 4878.88 LAKHS* TO THE ELIGIBLE EQUITY SHAREHOLDERS ON RIGHTS BASIS IN THE RATIO OF 5 (FIVE) PARTLY PAID UP EQUITY SHARES FOR EVERY 7 (SEVEN) FULLY PAID UP EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, I.E. 28TH APRIL, 2026 (THE “ISSUE”). THE ISSUE PRICE IS 1.5 TIMES OF FACE VALUE OF THE EQUITY SHARES. FOR FURTHER DETAILS, PLEASE SEE THE CHAPTER TITLED “TERMS OF THE ISSUE” ON PAGE 119 OF THIS LETTER OF OFFER. *assuming full subscription PAYMENT METHOD FOR RIGHTS EQUITY SHARES Amount Payable per equity share Face value (₹) Premium (₹) Total (₹) On Application 2.50 1.25 3.75 One or more subsequent call(s) as determined by our board / committee at its sole discretion, from 7.50 3.75 11.25 time to time Total 10.00 5.00 15.00 GENERAL RISK Investment in equity and equity related securities involve a degree of risk and investors should not invest any funds in the Issue unless they can afford to take the risk with such investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors shall rely on their own examination of our Company and the Issue including the risks involved. The securities being offered in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI") nor does SEBI guarantee the accuracy or adequacy of this Letter of Offer. Specific attention of the investors is invited to "Risk Factors" beginning on page 24 of this Letter of Offer before making an investment in this Issue. WILFUL DEFAULTER OR A FRAUDULENT BORROWER Neither our Company nor any of our Promoters or Directors has been categorized as a Wilful Defaulter or a Fraudulent Borrower by any bank or financial institution (as defined under the Companies Act, 2013) or consortium thereof, in accordance with the guidelines on Wilful Defaulter or a Fraudulent Borrower issued by the Reserve Bank of India. ISSUER’S ABSOLUTE RESPONSIBILITY Our Company, having made all reasonable inquiries, accepts responsibility for and confirms that this Letter of offer contains all information with regard to our Company and the Issue, which is material in the context of this Issue; that the information contained in this Letter of offer is true and correct in all material aspects and is not misleading in any material respect; that the opinions and intentions expressed herein are honestly held; and that there are no other facts, the omission of which makes this Letter of offer as a whole or any of such information or the expression of any such opinions or intentions misleading in any material respect. LISTING The existing Equity Shares of our Company are listed on the BSE Limited (“BSE”). Our Company has received “in- principle” approval from BSE for listing the Equity Shares to be allotted pursuant to the Issue through its letter dated 19th September, 2025. Our Company will also make an application to BSE to obtain its trading approval for the right entitlements as required under the SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020. For the purpose of this Issue, the Designated Stock Exchange is BSE. Indrayani Biotech Limited (CIN- L40100TN1992PLC129301) Letter of Offer REGISTRAR TO THE ISSUE MUFG INTIME INDIA PRIVATE LIMITED (Formerly Known as Link Intime India Private Limited) Office No.: C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg, Vikhroli (West), Mumbai-400083. Tel No.: 022-49186200/ +91 8108114949; Fax No.: 022-49186195 E-mail ID: indrayani.rights@in.mpms.mufg.com Contact Person: Mrs. Shanti Gopalakrishnan Website: https://in.mpms.mufg.com SEBI Registration Number: INR000004058 ISSUE PROGRAMME ISSUE OPENS ON LAST DATE OF ON-MARKET RENUNCIATIONS* ISSUE CLOSES ON** Tuesday, 15th September, 2026 Friday, 8th October, 2026 Tuesday, 14th October, 2026 *Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncee(s) on or prior to the Issue Closing Date. **Our Board or rights issue committee thereof will have the right to extend the Issue period as it may determine from time to time but not exceeding 30 (thirty) days from the Issue Opening Date (inclusive of the Issue Opening Date). Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date. Indr [Showing first 8,000 characters — download PDF for full document]